AI startup Anthropic has launched Claude Science, a specialised workbench that has been built to help scientists quickly analyse complex data, manage heavy computer workflows and accelerate breakthroughs. The new platform marks an expansion for the IPO-bound tech company into the healthcare and life sciences sector, where Google DeepMind has already got success in the form of Alphafold – an AI system that predicts a protein’s 3D structure from its amino acid sequence.
Claude Science is an initiative Anthropic has been reportedly building out since October 2025. By providing an interface tailored purely for academic and medical research, the tool aims to take the mechanical tediousness out of laboratory data management.
Unified workspace for global research
Claude Science serves as an all-in-one digital laboratory, combining coding tools, processing power and scientific databases into a single screen. According to Anthropic, the platform allows researchers to instantly review and cross-reference thousands of pages of existing medical literature.
Further, it also processes raw data and instantly generate publication-ready charts and manuscript drafts. Thirdly, scientists can use the tool to map final research figures back to the exact code and laboratory environment where they were created, ensuring transparency.
To ensure scientists have the right tools out of the box, Anthropic pre-configured the system with more than 60 massive scientific databases. The interface can also natively render complex, highly technical visual data, including 3D protein structures, chemistry molecular models and genome browser tracks.
Anthropic says Claude Science is built with safety in mind
Anthropic says that Claude Science runs on its existing family of advanced models. The system has successfully cleared the company’s “responsible scaling” policies and specialised biosecurity evaluations to ensure the powerful technology cannot be misused.During a press briefing announcing the launch, Eric Kauderer-Abrams, Anthropic’s Head of Life Sciences, revealed that the company is also launching its own internal, pre-clinical drug discovery programs. Anthropic plans to use Claude Science to hunt for treatments for neglected diseases.
